IMVT

ImmunovantA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

earnings

Source

External coverage

Decided

2026-05-21

Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update

View event details1 more curated

Sentiment decomposition

0.0

30-day score

Company-55%

Macro-30%

Pulse-15%

The 30-day sentiment score is a decayed blend of Company, Macro, and Pulse components.

Recent headlines

Headline

Time

Relevance

Immunovant Stock Surges 22% on Trial Data. Earnings Are an Afterthought.

2026-05-20

55%

External coverage

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

2026-05-20

23%

External coverage

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

2026-05-11

External coverage

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

2026-04-02

23%

External coverage

Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards?

2026-02-19

External coverage

Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards?

2026-02-17

External coverage

As of 2026-05-21 • Updated scheduledSource: News desk